BR112016003030A2 - anticorpos iib do receptor anti-fc-gama e uso dos mesmos - Google Patents

anticorpos iib do receptor anti-fc-gama e uso dos mesmos

Info

Publication number
BR112016003030A2
BR112016003030A2 BR112016003030A BR112016003030A BR112016003030A2 BR 112016003030 A2 BR112016003030 A2 BR 112016003030A2 BR 112016003030 A BR112016003030 A BR 112016003030A BR 112016003030 A BR112016003030 A BR 112016003030A BR 112016003030 A2 BR112016003030 A2 BR 112016003030A2
Authority
BR
Brazil
Prior art keywords
gamma receptor
receptor iib
antibodies
iib antibodies
fcibri
Prior art date
Application number
BR112016003030A
Other languages
English (en)
Inventor
Carle Anna
Ehehalt Daniela
Ter Meer Dominik
Rieth Nicole
Sondermann Peter
Pohl Thomas
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of BR112016003030A2 publication Critical patent/BR112016003030A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)

Abstract

a presente invenção refere-se a um anticorpo anti-fc¿riib que, em comparação com os anticorpos da técnica anterior, aumenta de forma marcante a fosforilação do itim de fc¿riib e pode assim ser utili-zado para o tratamento ou profilaxia de doenças autoimunes.
BR112016003030A 2013-08-16 2014-08-13 anticorpos iib do receptor anti-fc-gama e uso dos mesmos BR112016003030A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13004094.2A EP2837637A1 (en) 2013-08-16 2013-08-16 Novel anti-FcyRIIB IgG-type antibody
PCT/EP2014/002234 WO2015022077A1 (en) 2013-08-16 2014-08-13 Novel anti-fc-gamma receptor iib antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112016003030A2 true BR112016003030A2 (pt) 2017-09-12

Family

ID=49000296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003030A BR112016003030A2 (pt) 2013-08-16 2014-08-13 anticorpos iib do receptor anti-fc-gama e uso dos mesmos

Country Status (24)

Country Link
US (1) US10407499B2 (pt)
EP (2) EP2837637A1 (pt)
JP (2) JP6775420B2 (pt)
KR (1) KR102385790B1 (pt)
CN (1) CN105636987B (pt)
AU (1) AU2014308143B2 (pt)
BR (1) BR112016003030A2 (pt)
CA (1) CA2921251C (pt)
CL (1) CL2016000349A1 (pt)
DK (1) DK3033357T3 (pt)
EA (1) EA035855B1 (pt)
ES (1) ES2668482T3 (pt)
HK (1) HK1224302A1 (pt)
HR (1) HRP20180664T1 (pt)
HU (1) HUE038977T2 (pt)
IL (1) IL244135B (pt)
MX (1) MX2016002027A (pt)
MY (1) MY174711A (pt)
NO (1) NO3033357T3 (pt)
PL (1) PL3033357T3 (pt)
PT (1) PT3033357T (pt)
SG (1) SG11201600930RA (pt)
SI (1) SI3033357T1 (pt)
WO (2) WO2015022076A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
MY180940A (en) 2014-08-13 2020-12-14 Suppremol Gmbh Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
AU2019242586A1 (en) * 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
ATE536188T1 (de) * 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
WO2005018669A1 (en) * 2003-08-18 2005-03-03 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
US8853363B2 (en) 2003-11-26 2014-10-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Substance binding human IgG Fc receptor IIb (FcγRIIb)
WO2005115452A2 (en) * 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
PL1960427T3 (pl) 2005-12-13 2011-07-29 Suppremol Gmbh Multimeryczne polipeptydy receptora Fc
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CA2705164A1 (en) 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies
EP2234641B1 (en) * 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b
WO2009158696A1 (en) 2008-06-27 2009-12-30 Zymogenetics, Inc. SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
MY180940A (en) 2014-08-13 2020-12-14 Suppremol Gmbh Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Also Published As

Publication number Publication date
EA035855B1 (ru) 2020-08-20
HK1224302A1 (zh) 2017-08-18
AU2014308143B2 (en) 2019-10-31
JP2020048562A (ja) 2020-04-02
PT3033357T (pt) 2018-05-18
KR102385790B1 (ko) 2022-04-12
EP2837637A1 (en) 2015-02-18
HRP20180664T1 (hr) 2018-07-13
EA201690383A1 (ru) 2016-06-30
JP2016530256A (ja) 2016-09-29
MY174711A (en) 2020-05-10
IL244135B (en) 2020-02-27
US20160185857A1 (en) 2016-06-30
US10407499B2 (en) 2019-09-10
WO2015022076A1 (en) 2015-02-19
EP3033357A1 (en) 2016-06-22
JP6775420B2 (ja) 2020-10-28
WO2015022077A1 (en) 2015-02-19
CN105636987B (zh) 2020-07-31
MX2016002027A (es) 2016-05-16
AU2014308143A1 (en) 2016-03-03
NO3033357T3 (pt) 2018-07-14
CA2921251A1 (en) 2015-02-19
EP3033357B1 (en) 2018-02-14
IL244135A0 (en) 2016-04-21
CL2016000349A1 (es) 2016-11-04
HUE038977T2 (hu) 2018-12-28
SI3033357T1 (en) 2018-07-31
SG11201600930RA (en) 2016-03-30
KR20160036631A (ko) 2016-04-04
DK3033357T3 (en) 2018-05-22
PL3033357T3 (pl) 2018-08-31
WO2015022077A8 (en) 2015-12-03
CA2921251C (en) 2023-01-24
ES2668482T3 (es) 2018-05-18
CN105636987A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
BR112016000903A2 (pt) anticorpos
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
BR112017010762A2 (pt) anticorpos anti-pd-1 e métodos de uso dos mesmos
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112017027549A2 (pt) anticorpo para cd40
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112017011932A8 (pt) Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
BR112015022260A8 (pt) imunoterapia com tau
BR112017002342A2 (pt) novos anticorpos e usos dos mesmos
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
BR112017005522A2 (pt) abas de aplicação heterogênea
BR112016025470A2 (pt) ?hdl terapêutico?
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]